Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EDP1503 |
Synonyms | |
Therapy Description |
EDP1503 is an oral dose of monoclonal Bifidobacterium, which may induce an antitumor immune response and inhibition of tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS11-27). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EDP1503 | EDP 1503|EDP-1503 | Microbiome 7 | EDP1503 is an oral dose of monoclonal Bifidobacterium, which may induce an antitumor immune response and inhibition of tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS11-27). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |